United States Patent 9,180,200: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 9,180,200, titled "Pharmaceutical topical compositions," is a significant patent in the pharmaceutical industry, particularly for the treatment of certain medical conditions using topical formulations. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.
Patent Overview
Patent Number and Title
- Patent Number: US9180200
- Title: Pharmaceutical topical compositions[2].
Patent Owner
The patent is owned by Ferrer Internacional Sa, a pharmaceutical company known for its innovative drug formulations[2].
Scope of the Patent
Medical Applications
The patent covers pharmaceutical topical compositions, specifically designed for the treatment of sexually transmitted diseases and genital tract infections. These compositions are formulated to provide effective topical treatment, enhancing patient comfort and efficacy[5].
Composition Details
The patent describes stable topical cream compositions that include specific active ingredients and excipients. These formulations are optimized for topical application, ensuring stability and bioavailability of the active ingredients[5].
Claims of the Patent
Active Ingredients and Formulations
The patent claims include various aspects of the pharmaceutical topical compositions:
- Active Ingredients: The patent specifies the use of particular active ingredients, such as quinolonecarboxylic acid derivatives or other pharmacologically active compounds[5].
- Formulation: The claims cover the specific formulations, including the types of excipients, solvents, and stabilizers used to maintain the stability and efficacy of the topical compositions[5].
Mode of Administration
The patent also covers the mode of administration, which includes topical application methods such as creams, gels, and ointments. This ensures that the formulation is delivered effectively to the targeted area[5].
Patent Expiration and Status
Current Status
As of the current date, the patent US9180200 is active and will expire on January 29, 2032[2].
Legal Activities
The patent has undergone various legal activities, including the payment of maintenance fees and issue notifications. These activities are crucial in maintaining the patent's validity and ensuring its protection until the expiration date[2].
Patent Landscape
Family Patents
The patent US9180200 is part of a family of patents that protect the active ingredient and various aspects of the drug. Understanding the family patents is essential for strategizing market entry and identifying potential generic entry points[2].
Global Protection
While the patent provides protection within the United States, it is also protected in multiple countries. This global protection is vital for maintaining exclusivity and preventing unauthorized generic launches in different markets[2].
Exclusivities
Xepi, the drug associated with this patent, holds exclusivities such as New Chemical Entity (NCE) exclusivity, which expired in December 2022. However, the patent itself remains a significant barrier to generic competition until its expiration[2].
Impact on Generic Launch
Generic Launch Date
The estimated generic launch date for Xepi, based on the patent expiration and exclusivities, is January 29, 2032. This date can be influenced by legal activities such as patent term extensions or challenges to the patent[2].
Market Strategy
Understanding the patent landscape and the expiration dates of related patents is crucial for pharmaceutical companies planning to launch generic versions of the drug. Identifying markets with weaker patent protection can provide strategic advantages for early generic entry[2].
Tools for Patent Analysis
USPTO Resources
The United States Patent and Trademark Office (USPTO) provides several tools and resources for analyzing patents, including the Patent Public Search tool, Global Dossier, and the Patent Examination Data System (PEDS). These tools help in tracking patent activities, family patents, and legal events[4].
Common Citation Document (CCD)
The Common Citation Document (CCD) application consolidates prior art cited by participating offices, enabling a comprehensive view of the patent family and its global implications[4].
Key Takeaways
- Patent Scope: Covers pharmaceutical topical compositions for treating sexually transmitted diseases and genital tract infections.
- Claims: Includes specific active ingredients, formulations, and modes of administration.
- Expiration: Active until January 29, 2032.
- Global Protection: Protected in multiple countries, affecting global market strategies.
- Exclusivities: NCE exclusivity expired in December 2022, but patent remains a barrier to generics.
- Generic Launch: Estimated launch date is January 29, 2032, subject to legal activities.
FAQs
What is the main focus of United States Patent 9,180,200?
The main focus of this patent is on pharmaceutical topical compositions, particularly for the treatment of sexually transmitted diseases and genital tract infections.
Who owns the patent US9180200?
The patent is owned by Ferrer Internacional Sa.
When is the patent US9180200 set to expire?
The patent is set to expire on January 29, 2032.
What are the key claims of the patent?
The key claims include the specific active ingredients, formulations, and modes of administration for the topical compositions.
How does the patent landscape affect generic drug launches?
The patent landscape, including family patents and global protection, significantly affects generic drug launches by setting barriers and defining the timing of generic entry.
What tools can be used to analyze patents like US9180200?
Tools such as the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) can be used to analyze patents and their global implications.
Sources
- US9181200B2 - Pyrimidinedione compounds - Google Patents
- Xepi patent expiration - Pharsight - GreyB
- Patent Claims Research Dataset - USPTO
- Search for patents - USPTO
- United States Patent - googleapis.com
